Morgan Stanley’s Aevi Genomic Medicine Inc GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-1,000
| Closed | – | – | 6906 |
|
|
2019
Q4 | $0 | Hold |
1,000
| – | – | ﹤0.01% | 6882 |
|
|
2019
Q3 | $0 | Sell |
1,000
-2,498
| -71% | -$451 | ﹤0.01% | 6881 |
|
|
2019
Q2 | $0 | Sell |
3,498
-123
| -3% | -$25 | ﹤0.01% | 6860 |
|
|
2019
Q1 | $0 | Sell |
3,621
-7,004
| -66% | -$1.55K | ﹤0.01% | 6808 |
|
|
2018
Q4 | $6K | Buy |
10,625
+3,313
| +45% | +$3.7K | ﹤0.01% | 6287 |
|
|
2018
Q3 | $9K | Buy |
7,312
+2,171
| +42% | +$2.43K | ﹤0.01% | 6339 |
|
|
2018
Q2 | $6K | Buy |
5,141
+1,631
| +46% | +$2.48K | ﹤0.01% | 6417 |
|
|
2018
Q1 | $7K | Sell |
3,510
-5,202
| -60% | -$9.77K | ﹤0.01% | 6351 |
|
|
2017
Q4 | $11K | Buy |
8,712
+1,669
| +24% | +$2.28K | ﹤0.01% | 6203 |
|
|
2017
Q3 | $9K | Sell |
7,043
-48,937
| -87% | -$62.5K | ﹤0.01% | 6200 |
|
|
2017
Q2 | $74K | Buy |
55,980
+12,624
| +29% | +$18.2K | ﹤0.01% | 5746 |
|
|
2017
Q1 | $81K | Sell |
43,356
-41,514
| -49% | -$188K | ﹤0.01% | 5677 |
|
|
2016
Q4 | $440K | Buy |
84,870
+74,113
| +689% | +$390K | ﹤0.01% | 5007 |
|
|
2016
Q3 | $60K | Buy |
10,757
+4,649
| +76% | +$26.5K | ﹤0.01% | 5519 |
|
|
2016
Q2 | $34K | Sell |
6,108
-664
| -10% | -$3.49K | ﹤0.01% | 5669 |
|
|
2016
Q1 | $29K | Sell |
6,772
-484
| -7% | -$1.99K | ﹤0.01% | 5813 |
|
|
2015
Q4 | $43K | Sell |
7,256
-6,335
| -47% | -$43K | ﹤0.01% | 5774 |
|
|
2015
Q3 | $106K | Buy |
13,591
+3,827
| +39% | +$29.7K | ﹤0.01% | 5396 |
|
|
2015
Q2 | $59K | Buy |
9,764
+1,888
| +24% | +$14.6K | ﹤0.01% | 5801 |
|
|
2015
Q1 | $63K | Buy |
7,876
+2,700
| +52% | +$20.4K | ﹤0.01% | 5710 |
|
|
2014
Q4 | $27K | Buy |
5,176
+1,200
| +30% | +$5.93K | ﹤0.01% | 5986 |
|
|
2014
Q3 | $21K | Buy |
3,976
+500
| +14% | +$3.23K | ﹤0.01% | 5993 |
|
|
2014
Q2 | $27K | Sell |
3,476
-40,952
| -92% | -$289K | ﹤0.01% | 5947 |
|
|
2014
Q1 | $311K | Buy |
44,428
+42,028
| +1,751% | +$328K | ﹤0.01% | 4869 |
|
|
2013
Q4 | $14K | Sell |
2,400
-25,225
| -91% | -$165K | ﹤0.01% | 5964 |
|
|
2013
Q3 | $215K | Buy |
+27,625
| New | +$128K | ﹤0.01% | 4840 |
|
Morgan Stanley's GNMX Position: Q1 2020 in Review
Morgan Stanley sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 1,000 shares.
Morgan Stanley first reported a position in GNMX in Q3 2013 and held it in 26 quarters. The position peaked at $440K in Q4 2016. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.
- Morgan Stanley reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
- Morgan Stanley sold 1,000 Aevi Genomic Medicine Inc shares in Q1 2020.
- Morgan Stanley first reported a position in Aevi Genomic Medicine Inc in Q3 2013 and held it in 26 quarters.
- Morgan Stanley's Aevi Genomic Medicine Inc position peaked at $440K in Q4 2016.
- 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.
Based on Morgan Stanley's 13F filing for Q1 2020, filed 15 May 2020.